Core Insights - The pharmaceutical sector is experiencing a rise, with the Shanghai Stock Exchange Sci-Tech Innovation Board Biomedicine Index increasing by 1.03% as of December 4, 2025, with notable gains from companies like Zai Lab (up 4.47%) and Rongchang Bio (up 4.14%) [1] Industry Overview - The pharmaceutical industry has undergone eleven rounds of national drug centralized procurement and multiple rounds of medical insurance negotiations, leading to an inevitable decline in the generic drug sector, which impacts the overall pharmaceutical industry [1] - From January to September 2025, the pharmaceutical manufacturing industry's revenue remained relatively stable, but the outlook for generic drugs is bleak, indicating a need for innovative drugs to drive future growth [1] Investment Perspective - According to Everbright Securities, future investments in the pharmaceutical sector should focus on the clinical value of drugs, addressing clinical needs of patients, as both domestic medical insurance policies and global expansion strategies increasingly emphasize clinical value [1] - The innovative drug industry chain and innovative medical devices are viewed positively based on the clinical value framework [1] Market Data - As of November 28, 2025, the top ten weighted stocks in the Shanghai Stock Exchange Sci-Tech Innovation Board Biomedicine Index include companies like United Imaging Healthcare and BeiGene, collectively accounting for 49.75% of the index [1]

Group 1 - Guizhou BaiLing's actual controller Jiang Wei has been investigated by the China Securities Regulatory Commission (CSRC) for insider trading and information disclosure violations [1] - The investigation highlights the regulatory focus on key individuals and may increase operational uncertainty for Guizhou BaiLing, which has faced performance pressures in recent years [1] - The CSRC's actions reflect ongoing efforts to enhance the rule of law in the capital market [1] Group 2 - Jianyou Co., Ltd. has received ANDA approval from the FDA for its Propofol emulsion injection, marking a significant step in the company's internationalization of its formulations [2] - The product is expected to have a broad market potential in the U.S. as a commonly used sedative for surgeries, potentially driving revenue growth for the company [2] Group 3 - Shenzhen Xinlitai has been granted clinical trial approval for its innovative small molecule drug SAL0140, aimed at treating chronic kidney disease (CKD) [3] - SAL0140 is a proprietary aldosterone synthase inhibitor with potential applications in multiple significant chronic disease areas, indicating substantial market potential [3] - Successful development could open new growth avenues for Shenzhen Xinlitai [3] Group 4 - Junshi Biosciences reported a decrease in the shareholding percentage of Greenland Financial Investment Group and its affiliates from 5.0051% to 4.7129% due to share lending [4] - This change is a technical operation rather than an active reduction in holdings, but it brings the shareholding below the 5% disclosure threshold, warranting market attention on future actions [4] Group 5 - Sichuan Sichuang Medical Technology Co., Ltd. announced the resignation of Chairman Xu Yiran to facilitate governance structure optimization, while he will remain a board member [5] - The appointment of Wei Naixu as the new chairman indicates a strategic move to clarify responsibilities and strengthen governance rather than a response to a crisis [5]

Group 1 - Guizhou BaiLing's actual controller Jiang Wei has been investigated by the China Securities Regulatory Commission (CSRC) for insider trading and information disclosure violations, indicating a focus on regulatory enforcement against key individuals [1] - The investigation may exacerbate operational uncertainties for Guizhou BaiLing, which has faced performance pressures in recent years, raising concerns about corporate governance and information disclosure risks [1] Group 2 - Jianyou Co., Ltd. has received ANDA approval from the FDA for its propofol emulsion injection, marking a significant step in the company's internationalization of its formulations [2] - The product, commonly used for sedation during surgeries, has substantial market potential in the U.S., which is expected to contribute to revenue growth for Jianyou [2] Group 3 - Shenzhen Xinlitai Pharmaceutical Co., Ltd. has been granted clinical trial approval for its innovative small molecule drug SAL0140, aimed at treating chronic kidney disease (CKD) [3] - SAL0140, an aldosterone synthase inhibitor, targets multiple significant chronic disease areas, including uncontrolled hypertension and CKD, presenting considerable market potential for the company [3] Group 4 - Junshi Biosciences reported a decrease in the shareholding percentage of Greenland Financial Investment Group and its affiliates from 5.0051% to 4.7129% due to share lending, falling below the 5% disclosure threshold [4] - This change is primarily a technical operation rather than an active reduction in holdings, but the market will need to monitor the future actions of these shareholders [4] Group 5 - Sichuang Medical Technology has elected Wei Naixu as the new chairman following the resignation of Xu Yiran, who stepped down to facilitate governance structure optimization [5] - Xu Yiran will remain on the board, indicating that the adjustment aims to clarify responsibilities and strengthen governance rather than signaling a crisis [5]

本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息一致。 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688180 证券简称：君实生物 公告编号：临2025-069 上海君实生物医药科技股份有限公司 关于持股5%以上股东权益变动 触及5%刻度的提示性公告 上海君实生物医药科技股份有限公司（以下简称"公司"）持股5%以上股东绿地金融投资控股集团有限 公司（以下简称"绿地金融"）、上海加财投资管理有限公司（以下简称"上海加财"）、Greenland Financial Overseas Investment Group Co., Ltd（以下简称"Greenland"）保证向本公司提供的信息真实、准 确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： ■ 一、信息披露义务人及其一致行动人的基本信息 （一）身份类别 ■ （二）信息披露义务人信息 ■ （三）一致行动人信息 ■ 二、权益变动触及5%刻度的基本情况 公司于2025年12月3日收到持股5%以上股东绿地金融、上海加财及Greenland关于相关权益变动情况的通 知，因经营需要，Greenland进行H股股份出借，导致绿地 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條規則作出。 茲載列上海君實生物醫藥科技股份有限公司在上海證券交易所網站刊發之《上海 君實生物醫藥科技股份有限公司簡式權益變動報告書》，僅供參閱。 承董事會命 上海君實生物醫藥科技股份有限公司 熊俊先生 主席 SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* 上海君實生物醫藥科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1877） 海外監管公告 中國，上海，2025年12月3日 於本公告日期，本公司董事會包括執行董事熊俊先生、李寧博士、鄒建軍博士、 李聰先生、張卓兵先生、姚盛博士、王剛博士及李鑫博士；非執行董事湯毅先 生；以及獨立非執行董事張淳先生、馮曉源博士、酈仲賢先生、魯琨女士及楊勁 博士。 * 僅供識別之用 上海君实生物医药科技股份有限公司 简式权益变动报告书 上市公司名称：上海君实 ...

SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 上海君實生物醫藥科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1877） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條規則作出。 茲載列上海君實生物醫藥科技股份有限公司在上海證券交易所網站刊發之《上海 君實生物醫藥科技股份有限公司關於持股5%以上股東權益變動觸及5%刻度的提 示性公告》，僅供參閱。 承董事會命 上海君實生物醫藥科技股份有限公司 熊俊先生 主席 中國，上海，2025年12月3日 於本公告日期，本公司董事會包括執行董事熊俊先生、李寧博士、鄒建軍博士、 李聰先生、張卓兵先生、姚盛博士、王剛博士及李鑫博士；非執行董事湯毅先 生；以及獨立非執行董事張淳先生、馮曉源博士、酈仲賢先生、魯琨女士及楊勁 博士。 * 僅供識別之用 （一）身份类别 | | □控股股东/实际 ...

证券代码：688180 证券简称：君实生物 公告编号：临 2025-069 上海君实生物医药科技股份有限公司 关于持股 5%以上股东权益变动 触及 5%刻度的提示性公告 上海君实生物医药科技股份有限公司（以下简称"公司"）持股 5%以上股东绿地 金融投资控股集团有限公司（以下简称"绿地金融"）、上海加财投资管理有限公司（以 下简称"上海加财"）、Greenland Financial Overseas Investment Group Co., Ltd（以下 简称"Greenland"）保证向本公司提供的信息真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： | 权益变动方向 | 比例增加□ | | 比例减少√ | | --- | --- | --- | --- | | 权益变动前合计比例 | 5.0051% | | | | 权益变动后合计比例 | 4.7129% | | | | 本次变动是否违反已作出的承 诺、意向、计划 | 是□ | 否√ | | | 是否触发强制要约收购义务 | 是□ | 否√ | | 一、 信息披 ...

信息披露义务人名称：上海加财投资管理有限公司 住所：上海市嘉定区安亭镇曹安公路 5128 号 1 幢 1 层 1155 室 通讯地址：上海市黄浦区龙华东路 868 号办公 A1204 室 信息披露义务人名称：Greenland Financial Overseas Investment Group Co., Ltd 住所：Unit 8, 3/F., Qwomar Trading Complex, Blackburne Road, Port Purcell, Road Town,Tortola, British Virgin Islands 通讯地址：上海市黄浦区龙华东路 868 号办公 A 楼 1508 室 股份变动性质：H 股股份出借导致权益比例降低至 5%以下。 签署日期：2025 年 12 月 3 日 上市地点：上海证券交易所/香港联合交易所 股票简称：君实生物 股票代码：688180（A 股）、01877（H 股） 信息披露义务人声明 一、信息披露义务人根据《中华人民共和国证券法》（以下简称"《证券法》"）、 《上市公司收购管理办法》（以下简称"《收购办法》"）、《公开发行证券的公司 信息披露内容与格 ...

君实生物公告称，2025年12月3日收到持股5%以上股东绿地金融、上海加财及Greenland通知，因经营需 要，Greenland于12月2日进行H股股份出借，致三者合计持股由5138.64万股降至4838.64万股，占总股本 比例由5.0051%降至4.7129%，权益变动触及5%刻度。本次变动不触及要约收购，不涉及资金来源，也 不会使公司控股股东及实际控制人发生变化。 ...

Group 1 - The Hong Kong Innovation Drug ETF (159570) experienced a 1.5% decline, marking its fourth consecutive day of decrease, with a trading volume exceeding 1.3 billion yuan [1] - The ETF has attracted a net inflow of over 6 million yuan during the day and has accumulated over 740 million yuan in the last 10 days, with a total size exceeding 23.6 billion yuan as of December 2 [1] - Major weighted stocks in the ETF, such as 3SBio, Innovent Biologics, and China Biologic Products, saw declines of over 2%, while others like CSPC Pharmaceutical and BeiGene dropped over 1% [2][3] Group 2 - The upcoming ASH conference is expected to reveal key data in the hematology field, which may catalyze the valuation recovery of related pipelines, particularly for companies with differentiated advantages in oncology, autoimmune, and rare disease products [5] - The Chinese innovative drug industry has shown significant growth, with the number of clinical trials increasing from 1,473 in 2020 to 2,539 in 2024, reflecting a compound annual growth rate of over 15% [6][9] - Chinese pharmaceutical companies are becoming increasingly prominent in global research, contributing 27% in oncology and 19% in autoimmune fields, with significant positions in ADC targets such as HER2 and TROP2 [9]